Controlled Release of Cyclosporine a from Biodegradable Amphiphilic Diblock Copolymer Sol-gel Drug Delivery System
暂无分享,去创建一个
[1] So young Kim,et al. Reverse Thermal Gelling PEG−PTMC Diblock Copolymer Aqueous Solution , 2007 .
[2] Chaoliang He,et al. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[3] D. Brocks,et al. A novel use of an in vitro method to predict the in vivo stability of block copolymer based nano-containers. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[4] J. San Román,et al. Controlled release of cyclosporine from VP-HEMA copolymer systems of adjustable resorption monitorized by MEKC. , 2000, Biomaterials.
[5] D. Brocks,et al. Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution. , 2005, Biomaterials.
[6] T. Okano,et al. Preparation and characterization of thermally responsive block copolymer micelles comprising poly(N-isopropylacrylamide-b-DL-lactide). , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[7] Jan Feijen,et al. Effect of comonomer hydrophilicity and ionization on the lower critical solution temperature of N-isopropylacrylamide copolymers , 1993 .
[8] J. Doroshow,et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. , 2001, Blood.
[9] A. Lavasanifar,et al. Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[10] H. Ahmadieh,et al. Low dose cyclosporin-A therapy in Behçet's disease. , 1994, Journal of ocular pharmacology.
[11] S. Cho,et al. Preparation of methoxy poly(ethylene glycol)/polyester diblock copolymers and examination of the gel‐to‐sol transition , 2004 .
[12] P. Emery,et al. Clinical Use of Cyclosporin in Rheumatoid Arthritis , 2012, Drugs.
[13] W. Dalton,et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J Verweij,et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.
[15] S. Cho,et al. Preparation of poly(ethylene glycol)-block-poly(caprolactone) copolymers and their applications as thermo-sensitive materials. , 2004, Journal of biomedical materials research. Part A.
[16] Sung Wan Kim,et al. Poly(D,L-lactic acid-co-glycolic acid)-b-poly(ethylene glycol)-b-poly (D,L-lactic acid-co-glycolic acid) triblock copolymer and thermoreversible phase transition in water. , 2002, Journal of biomedical materials research.
[17] Sung Wan Kim,et al. Novel Thermoreversible Gelation of Biodegradable PLGA-block-PEO-block-PLGA Triblock Copolymers in Aqueous Solution , 2001 .
[18] J. Mestecky,et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[19] Q. Fang,et al. New Biodegradable Amphiphilic Block Copolymers of ε‐Caprolactone and δ‐Valerolactone Catalyzed by Novel Aluminum Metal Complexes , 2005 .
[20] J. Curtis,et al. Cyclosporine-induced nephrotoxicity: pathophysiology of decreased blood flow. , 1988, Transplantation proceedings.
[21] N. Yoshimura,et al. Dialysis and renal transplantation as renal replacement therapy for end-stage renal failure, with special reference to the ethical problems of living renal donation , 2001 .
[22] W. Bennett,et al. Chronic cyclosporine nephrotoxicity , 1998, Current opinion in nephrology and hypertension.